ABSTRACT NUMBER: ESOC2026A1800 CARDIAC MONITORING FOR DETECTION OF ATRIAL FIBRILLATION AFTER TIA: A SYSTEMATIC REVIEW AND META-ANALYSIS Authors: Alexander Veltkamp, Eleni Korompoki, Lucio D'anna, Manuel C Olma, Karl Georg Haeusler, Matthias Endres, Roland Veltkamp Published: 2026 ABSTRACT AbstractBackground and aimsThe optimal ECG monitoring method for sensitive detection of atrial fibrillation (AF) after TIAs is uncertain. This systematic review and meta-analysis aim to determine the rate of newly diagnosed AF using various ECG monitoring methods and durations after TIA.MethodsA literature search from 1966 through May 31, 2025, was conducted in accordance with PRISMA guidelines using a protocol registered in PROSPERO (CRD420251075716). Prospective observational studies and randomized controlled trials were considered that included TIA patients who underwent >12 hours of cardiac monitoring. Primary outcome was newly detected AF of ≥30 seconds duration, with subgroup analyses by monitoring duration and method.Results42 studies enrolling 3,981 TIA patients were included. The pooled AF detection rate was 6.5% (95% CI: 4.5–9.3%). Yield of monitoring was higher in in selected cohorts characterized by higher age, cryptogenic stroke etiology, and a more comprehensive diagnostic stroke workup than in unselected cohorts (8.95% vs 4.51%). Pooled AF detection rates rose with monitoring duration: 3.5% (1 day), 6.3% (7 days), 9.6% (30 days), 13.1% (90 days), 19.1% (12 months). Implantable cardiac monitors yielded a significantly higher AF detection rate than non-invasive cardiac monitoring (i.e., serial ECGs, 24-72h Holter, in-hospital telemetry) (20.8% vs. 4.7%). Substantial heterogeneity was observed among studies (I2 = 81.9%).ConclusionsThis meta-analysis including several studies with prolonged and invasive ECG monitoring found a high detection rate of AF in TIA patients. Randomized studies comparing the impact of different ECG monitoring methods on clinical endpoints are needed in TIA patients.Conflict of interestAlexander W Veltkamp: nothing to disclose. Eleni Korompoki: Speaker Honoraria/Advisory boards/Travel grants: Amgen, AstraZeneca, Bayer, Elpen, Innovis, Pfizer, Sanofi. Lucio D'Anna: nothing to disclose. Manuel C Olma: nothing to disclose. Karl Georg Haeusler: Speaker´s honoraria, consulting fees, lecture honoraria and/or study grants from Abbott, Amarin; Alexion, AstraZeneca, Bayer Healthcare, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Medtronic, Novartis, Pfizer, Portola, Premier Research, Sanofi, SUN Pharma, and W.L. Gore and Associates. Matthias Endres: funding from DFG under Germany´s Excellence Strategy – EXC-2049 – 390688087 , Collaborative Research Center ReTune TRR 295- 424778381, Clinical Research Group KFO 5023 BeCAUSE-Y, project 2 EN343/16-1, Research Group FOR 5930 AbsInVasc, project 6 EN343/18-1, BMBF, DZNE, DZHK, DZPG, and EU; grants from Bayer and Ipsen, and fees paid to the Charité from Amgen, AstraZeneca, Bayer Healthcare, BMS, Daiichi Sankyo, all outside the submitted work. Roland Veltkamp: research support from European Union’s Horizon 2020 research and innovation program under grant agreement No 754517, and from Bayer, BMS-Pfizer, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Biogen. Honoraria for consultancies and lectures for Astra Zeneca, Bayer, BMS-Pfizer, Javelin, Portola, and he is an investigator of the Imperial BRC.